Bringing you live news and features since 2006 

First cancer immunotherapy ETF now trading


The first ETF to exclusively hold shares of public companies that are engaged in the research and development of therapies that treat cancer through the body’s immune system has begun trading on the NASDAQ.

The Loncar Cancer Immunotherapy ETF (CNCR) is based on the Loncar Cancer Immunotherapy Index, an innovative index developed by biotechnology investor Brad Loncar (pictured), and has an expense ratio of 0.79 percent.
Exchange Traded Concepts, LLC (ETC) partnered with Loncar Investments, ISE ETF Ventures, and Amplify Development LLC on the launch.
The fund includes both large pharmaceutical and growth-oriented biotechnology companies that are leading this disruptive approach to cancer treatment. Bristol-Myers Squibb (4.15 per cent index weighting, ticker: BMY), Merck (3.89 per cent index weighting, ticker: MRK), Juno Therapeutics (3.53 per cent index weighting, ticker: JUNO) and Cellectis (2.98 per cent index weighting, ticker: CLLS) are four of the index’s thirty holdings. Twenty-three of the holdings are growth companies, while the remaining seven are large-cap, value equities.
“Immunotherapy is changing the way many cancers are being treated,” says Brad Loncar, Chief Executive Officer of Loncar Investments. “This innovative field within biotechnology is expected to become the foundational treatment for cancer over the next ten years. We think it is important to give investors a benchmark to track the progress of this growing biotechnology sector, which over time will likely continue to have a positive impact on society.”
“The science of cancer immunotherapy is one of the most exciting areas within biotechnology,” says J Garrett Stevens, CEO of Exchange Traded Concepts. “The Loncar Cancer Immunotherapy ETF allows investors to participate in the breakthrough in this well-defined sector in a diversified way. We are proud to deliver this product to the market.”
“We are excited to partner with Exchange Traded Concepts, Loncar Investments and Amplify Development to bring this new fund to market,” said Kris Monaco, Head of ISE ETF Ventures. “Our product portfolio focuses on funds that provide investors with exposure to targeted segments in first to market ETFs, and the Loncar Cancer Immunotherapy ETF is an outstanding fit with those objectives.”
“As the ETF market becomes more crowded, it can be challenging to find new investment themes that tap into a unique and compelling industry trend,” said Christian Magoon, CEO of Amplify Development LLC. “With his expertise in the biotechnology space, Brad Loncar has been able to do exactly that through the Loncar Cancer Immunotherapy Index, and I am pleased to partner with Brad, ETC and ISE ETF Ventures to offer this exciting new fund.”

Latest News

Morningstar has published a review of the European ETF market for the first quarter 2024, which finds that it gathered..
ETF data consultant ETFGI reports that assets invested in the global ETF industry reached a new record of USD12.71 trillion..
Calastone has published an ETF white paper which examines several of the processes that take place across the lifecycle of..
Adapting product lines to fit into changing methodologies and meet shifting demand is essential to remaining relevant in the industry..

Related Articles

Kristen Mierzwa, FTSE Russell
Index Investments Group (IIG), a division within index provider FTSE Russell, has extended its range of indices through two new...
US ETF issuers of active ETFs are facing an increase in fees from the big custodian firms, such as Charles...
Taylor Krystkowiak, Themes ETFs
Themes ETFs opened its doors in December 2023, with an introductory suite of 11 ETFs – seven thematic and four...
Konrad Sippel, Solactive
At the end of March, financial index specialist, Solactive, published its 2024 annual report on future trends.  ...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by